<unk>  (development codes NXL103 and XRP 2868) is an experimental drug candidate under development by Novexel. It is an oral streptogramin antibiotic that has potent in vitro activity against certain Gram-positive bacteria including methicillin resistant Staphylococcus aureus (MRSA), as well as the important respiratory pathogens including penicillin-, macrolide- and quinolone-resistant strains. It is a combination of<unk>  and<unk> .
Linopristin/flopristin
Isoniazid/pyridoxine/sulfamethoxazole/trimethoprim
Isoniazid/rifampicin
Benzathine benzylpenicillin
Rifampicin/isoniazid/pyrazinamide
Ethambutol/isoniazid/rifampicin
Rifabutin
Atazanavir/cobicistat